BCRX Biocryst Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 0 P/E
- 54.29 P/S
- 8.85 P/B
- -0.677 EPS
- -118.77% Cash ROIC
- 2.49 Cash Ratio
- 0 / 0% Dividend
- 881,345.00 Avg. Vol.
- 55.22M Shares
- 728.3M Market Cap.
BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
Ashburn Daily - 5 hours ago
Markets Wired - Feb 25, 2015
Price Target Update on BioCryst Pharmaceuticals, Inc. - Bar and Graph Report
Benzinga - Feb 18, 2015
BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results - CNNMoney
Seeking Alpha (registration) - Jan 27, 2015
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary ... - MarketWatch
Equities.com - Feb 24, 2015
BioCryst Pharmaceuticals Shares Up 6.6% Following Insider Buying Activity ... - Dakota Financial News
Wall Street Pulse - Feb 24, 2015
Equities.com - Feb 23, 2015
Stafford Daily - Feb 3, 2015
Markets Wired - Jan 29, 2015
Ashburn Daily - Feb 2, 2015